Extended Interval Dosing of Ocrelizumab in Patients with Multiple Sclerosis Is Not Associated with Meaningful Differences in Disease Activity

被引：0
|
作者：
Rjeily, N. Bou [1 ]
Fitzgerald, K. C. [1 ]
Mowry, E. M. [1 ]
机构：
[1] Johns Hopkins Univ, Neurol, Baltimore, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P164
引用
下载
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] NK cell levels predict disease activity in patients with Multiple Sclerosis on Ocrelizumab/Rituximab therapy
    Dal Bello, Simone
    Lorenzut, Simone
    Saccomano, Emma
    Tereshko, Yan
    Cargnelutti, Daniela
    Cutuli, Daniela
    Gigli, Gian Luigi
    Valente, Mariarosaria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 944 - 945
  • [32] NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy
    Dal Bello, Simone
    Lorenzut, Simone
    Saccomano, Emma
    Tereshko, Yan
    Gigli, Gian Luigi
    Pucillo, Carlo Ennio
    Valente, Mariarosaria
    PHARMACEUTICALS, 2024, 17 (02)
  • [33] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
    van Kempen, Zoe L. E.
    Hogenboom, Laura
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 693 - 695
  • [34] Ocrelizumab extended dosing in Primary Progressive Multiple Sclerosis during the COVID-19 pandemic: a multicenter experience
    D'Amico, E.
    Avolio, C.
    Lus, G.
    Bonavita, S.
    Ferraro, D.
    Callari, G.
    Barone, S.
    Patti, F.
    Granella, F.
    Zanghi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 1007 - 1008
  • [35] Extended interval dosing natalizumab and cognitive function in relapsing-remitting multiple sclerosis patients: a retrospective audit
    Mc Manus, E.
    Clark, K.
    Macniven, J.
    Schepel, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 503 - 504
  • [36] A systematic review and meta-analysis of extended interval dosing (EID) vs. standardinterval dosing (SID) of Natalizumab for multiple sclerosis patients
    Rabea, Eslam Mohammed
    Belal, Mohamed Mohamed
    Nourelden, Anas Zakarya
    Elbanna, Ashraf Hassan
    Khalifa, Mahmoud Ahmed
    Mahmoud, Nada H.
    Zaazouee, Mohamed Sayed
    NEUROLOGY, 2023, 100 (17)
  • [37] Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing
    Chang, Ih
    Muralidharan, Kumar Kandadi
    Campbell, Nolan
    Ho, Pei-Ran
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03): : 339 - 348
  • [38] Extended dosing of monoclonal antibodies in multiple sclerosis
    Kempen, Zoe L. E. van
    Toorop, Alyssa A.
    Sellebjerg, Finn
    Giovannoni, Gavin
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) : 2001 - 2009
  • [39] Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
    Toorop, Alyssa A.
    Noteboom, Samantha
    Steenwijk, Martijn D.
    Gravendeel, Job W.
    Jasperse, Bas
    Barkhof, Frederik
    Strijbis, Eva M. M.
    Rispens, Theo
    Schoonheim, Menno M.
    van Kempen, Zoe L. E.
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 266 - 271
  • [40] Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
    McManus, Eileen J.
    Clark, Karen M.
    Frampton, Christopher
    Macniven, Jamie A. B.
    Schepel, Jan
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2022, 8 (01)
12345